LungArchives
A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)
Lung 3 min.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated mortality worldwide. Nearly 20% of NSCLC patients develop liver metastases and these patients have lower response rates and worse survival after standard-of-care anti-programmed cell death protein 1/programmed death-ligand 1...
Effectiveness and safety of pirfenidone for radiation-induced lung injury in non-small cell lung cancer: a retrospective pilot study
Lung 5 min.
Radiation-induced lung injury (RILI) remains a major dose-limiting complication of thoracic radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC) [1]. Despite advances in RT techniques—including intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy...
Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials
Lung 4 min.
The advent of immune checkpoint inhibitors (ICIs) which target programmed cell death 1 (PD-1) or its ligand, PD-L1, has dramatically reshaped the landscape of cancer treatment. The combination of ICI with platinum-based chemotherapy has become the standard frontline therapy for various malignancies,...
Adagrasib versus docetaxel in KRAS
G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
Lung 1 min.
Adagrasib is a KRASG12C inhibitor that demonstrated promising activity against KRAS G12C-mutated advanced non-small-cell lung cancer (NSCLC) in a phase 2 trial. Here we aimed to compare the efficacy and safety of adagrasib versus docetaxel in patients with KRAS ...
Prognosis of non-small cell lung cancer patients undergoing compromised wedge vs. segmental resection: a population-based cohort study
Lung 4 min.
Surgery plays a central role in treating non-small cell lung cancer (NSCLC). A pivotal 1995 randomized controlled trial by the Lung Cancer Study Group established lobectomy as the standard of care, demonstrating that sublobar resection (SLR) had higher local recurrence rates and worse overall survival...
